Provisacor

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Provisacor

Provisacor is a synthetic, prescription-only medicine that acts as a potent lipid-lowering agent to manage elevated levels of fats in the blood. Its active ingredient is Rosuvastatin calcium, which belongs to the class of drugs known as statins.

Property Description
Active ingredient Rosuvastatin calcium
Form Oral formulation (Tablets)
Pharmacological class Statin (HMG-CoA Reductase Inhibitor)
General purpose Lowering LDL-C and reducing cardiovascular risk
Origin Synthetic compound

What Type of Medicine is Provisacor (Rosuvastatin)?

The medication is classified as an HMG-CoA reductase inhibitor, a category of antilipemic drugs used to adjust blood lipid levels. As a synthetic compound in its class, Rosuvastatin is used for achieving reductions in Low-Density Lipoprotein Cholesterol (LDL-C) levels. The primary indication of the Rosuvastatin component is as an adjunct to diet for the reduction of elevated Total-C and LDL-C levels in patients with primary hyperlipidemia and mixed dyslipidemia. It is supplied as an oral formulation in the form of compressed tablets.


How Does Rosuvastatin Fundamentally Affect Cholesterol?

The fundamental action of Rosuvastatin is the selective and competitive inhibition of the HMG-CoA reductase enzyme in the liver, which is a necessary step for the body’s internal production of cholesterol. This mechanism helps the body lower its own production of fats. By inhibiting this enzyme, the drug causes a reduction in the synthesis of total cholesterol and, specifically, LDL-C. This reduction in atherogenic lipids is observed in pharmacological evaluations and serves the general therapeutic purpose of cardiovascular risk reduction associated with the progression of atherosclerosis.

What side effects are possible with Provisacor?

The official safety profile of Provisacor (Rosuvastatin calcium) is defined by adverse reactions classified by frequency, affected system, and level of seriousness, as documented in regulatory sources such as the FDA and EMA.

Adverse Reactions by Classification

The most common side effects (reported in ge 2% of patients) are generally systemic, involving the Nervous System and Musculoskeletal and Gastrointestinal systems. These include headache, myalgia (muscle pain), asthenia (weakness), nausea, constipation, and abdominal pain.

Rare adverse reactions (affecting < 1 in 1,000 people) include rhabdomyolysis (severe muscle breakdown), pancreatitis, and hypersensitivity reactions such as angioedema. Post-marketing reports also note effects classified as incidence not known, such as cognitive impairment and immune-mediated necrotizing myopathy.

System-Organ Class Documented Common Effects
Musculoskeletal Myalgia, Asthenia
Gastrointestinal Nausea, Constipation, Abdominal Pain
Nervous System Headache

Serious Safety Considerations

The most serious documented concerns relate to the skeletal muscle and liver. These include: Rhabdomyolysis, a condition of severe muscle breakdown that can potentially lead to Acute Renal Failure. Hepatic Dysfunction (including jaundice and unexplained persistent elevations in liver enzymes) and severe hypersensitivity reactions are also explicitly listed as serious adverse events.

Safety Restrictions and Special Populations

Use of Provisacor is formally contraindicated in patients with active liver disease and during pregnancy and lactation. The risk of myopathy is documented as being higher at the maximum approved dose (40 mg). Furthermore, regulatory labels note that older adults (age ge 65) and individuals with severe renal impairment are at an increased risk for muscle-related adverse effects.

The official safety information structures the risk profile by classifying documented adverse reactions based on frequency and affected system, highlighting that while most effects are common and generally mild, the profile is formally defined by the explicit documentation of rare, but clinically serious, muscle and liver disorders.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that the effects resulting from an acute, single-dose overdosage of Provisacor (Rosuvastatin) in humans are not explicitly described. Management is focused on the immediate recognition and mitigation of known risks associated with high systemic exposure to statins.

Immediate Emergency Action

Immediate medical attention is required for any suspected overdose. Regulatory authorities advise contacting a poison control center expert or calling emergency services right away. This action is critical, particularly if the individual has collapsed, is having trouble breathing, or cannot be awakened.

Management and Monitoring

There is no specific antidote known for Rosuvastatin overdose. Treatment should be symptomatic and supportive measures instituted as required.

Due to the potential for serious outcomes, including rhabdomyolysis leading to acute renal failure and hepatic dysfunction, official labeling mandates urgent monitoring. This monitoring may include checking creatine kinase (CK) levels to assess for muscle breakdown and liver function (serum transaminases). A key procedural constraint noted by regulators is that hemodialysis is not expected to significantly enhance the clearance of the active substance from the body.

Therapeutic Uses of Provisacor

What Provisacor Treats: Main Uses and Benefits

Provisacor is a medicine used to address certain conditions and plays a role in managing factors associated with cardiovascular health. The key therapeutic uses are detailed below.


Supporting Systemic Stability

This medication is relevant in contexts that involve systemic imbalance, primarily by addressing symptoms related to systemic imbalance. It is commonly used across conditions presenting with acute or disruptive episodes where symptoms may intensify temporarily. This use is also relevant in contexts involving heightened systemic burden and supports the patient during episodes of heightened discomfort.


Key Therapeutic Domains

Provisacor is considered relevant in the supportive management of conditions associated with heightened cardiovascular risk, as well as for conditions involving episodic or fluctuating manifestations of systemic imbalance. It may assist with maintaining functional stability, which helps ease the overall symptom burden when symptoms become more noticeable.


Quick Facts
Support for Systemic Imbalance
Relevant for conditions with fluctuating manifestations
Used when short-term symptomatic assistance is needed

Regulatory References

  1. ROSUVASTATIN tablet, film coated - DailyMed - NIH

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Provisacor

The following is a summary of the official population eligibility and exclusion rules for Provisacor (rosuvastatin calcium), strictly based on governmental regulatory labeling.


Eligibility scope Status and Rules (Official Regulatory)
Populations Contraindicated Absolute prohibition for patients with active liver disease, known hypersensitivity to any component, women who are pregnant or may become pregnant, and nursing mothers (lactation) [1.1, 1.2].
Age-Related Eligibility Approved for adults with hyperlipidemia and for pediatric patients (children and adolescents) aged 7 or 8 years and older with specific forms of familial hypercholesterolemia [1.1]. Use is not established in children younger than 6 years [2.1].
Condition-Specific Restrictions Contraindicated in patients with severe renal impairment (creatinine clearance < 30 mL/min) for the maximum 40 mg dose [2.1]. Patients with predisposing factors for myopathy, such as uncontrolled hypothyroidism, require special consideration [1.5].
Population-Specific Limitations The 40 mg maximum dose is contraindicated for patients of Asian descent due to increased systemic exposure [1.5, 2.1]. Older adults ( 65 years) are listed as a predisposing factor for skeletal muscle effects [1.5].

Connection to the official eligibility profile Regulatory documents define who can and cannot use Provisacor by explicitly listing absolute contraindications based on physiological states (pregnancy, active liver disease) and by establishing restricted use based on predisposing factors (age 65, severe renal impairment) or genetic differences (Asian descent). These population-based rules categorize eligibility status across the life span and various chronic health conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Provisacor (Rosuvastatin calcium) is defined by officially documented effects on systemic drug exposure and additive risks for muscle toxicity, as established by regulatory authorities.

Interaction Scope

Detail Entity
Medicinal product categories with documented interactions: Immunosuppressants, Antivirals (HIV and Hepatitis C regimens), Lipid-modifying agents (Fibrates, Niacin), Coumarin Anticoagulants, and Antacids (Aluminum and Magnesium Hydroxide) [FDA Label; SmPC].
Specific interacting medicines (if explicitly listed): Cyclosporine, Gemfibrozil, Lopinavir/Ritonavir, Atazanavir/Ritonavir, Sofosbuvir/Velpatasvir/Voxilaprevir, Darolutamide, Regorafenib, Warfarin [NIH DailyMed; FDA Label].
Mechanistic basis of interactions (only if stated in label): Inhibition of drug transporters, primarily the hepatic uptake transporter OATP1B1 and the efflux transporter BCRP, leading to increased systemic exposure [SmPC]. Additive pharmacodynamic risk with certain medicines [FDA Label].
Timing-based interaction rules (if applicable): Mandatory requirement to administer Aluminum and Magnesium Hydroxide Antacids at least 2 hours after Rosuvastatin to prevent reduced absorption [FDA Label].
Population-specific interaction notes (if applicable): Asian patients may have increased systemic exposure and a higher risk for myopathy, which is an official consideration in the interaction profile [FDA Label].

Interaction-Related Restrictions and Classification

Official regulatory documents classify certain combinations based on risk:

  • Combinations Not Recommended: Co-administration with the combination product Sofosbuvir/Velpatasvir/Voxilaprevir is officially listed as not recommended. Co-administration with Gemfibrozil should be avoided due to a significant increase in rosuvastatin exposure and heightened myopathy risk [NIH DailyMed; FDA Label].
  • Increased Exposure: Medicines like Cyclosporine and certain Antivirals cause a substantial increase in rosuvastatin exposure, which is an official factor for dose limitation [FDA Label].
  • Pharmacodynamic Effect: Co-administration with Coumarin Anticoagulants (e.g., Warfarin) is documented to prolong the International Normalized Ratio (INR), requiring frequent monitoring upon initiation or alteration of rosuvastatin therapy [FDA Label].

These official statements define the necessary procedural and dose constraints required to manage interactions. The classification is aligned with standards set by the FDA and EMA.

Mechanism of Action

How Provisacor Works: Mechanism of Action

Provisacor's primary action involves acting as a competitive inhibitor of the enzyme HMG-CoA Reductase in the liver. This enzyme catalyzes the rate-limiting step of the Mevalonate pathway, which is the body's major route for endogenous cholesterol synthesis. By blocking this enzyme, the drug limits the production of new cholesterol, resulting in an alteration of the liver's intracellular cholesterol status.

This altered cellular state triggers a regulatory feedback mechanism that increases the expression and density of LDL receptors on the surface of liver cells. These upregulated receptors actively bind to and remove lipids, specifically LDL-C, from the systemic circulation, thereby accelerating their plasma clearance.

Furthermore, Provisacor modulates processes within the vascular endothelium, independent of its lipid-altering activity. This includes local modulation of inflammatory signaling and influencing endothelial function, which in turn influences the structural and functional properties of blood vessel walls.

Dosage and Administration Information

How Provisacor is Used

Provisacor (Rosuvastatin) is administered as an oral tablet and is typically taken once daily as part of a long-term therapeutic plan. Available dosage strengths include 5 mg, 10 mg, 20 mg, and 40 mg. The standard adult dosing regimen generally begins at 10 mg or 20 mg.


Dosing and Administration Protocol

The medicine may be taken at any time of day and is effective when administered with or without food. However, to ensure proper absorption, the dose must be separated by at least two hours before or four hours after taking an aluminum and magnesium hydroxide antacid.

Dosage adjustments, when needed, are based on patient response and are usually assessed by a healthcare provider at intervals of 2 to 4 weeks after initiation or change. The highest recommended daily dose is 40 mg, generally reserved for individuals who have not reached their treatment goals on the 20 mg dose.


Population-Specific Instructions

Specific dosage considerations apply to certain groups. Patients diagnosed with severe renal impairment (not on dialysis) should not exceed a maximum daily dose of 10 mg, and therapy should begin at 5 mg once daily. Additionally, a lower starting dose of 5 mg should be considered for certain Asian patients. If a dose is missed, individuals should not take an extra dose; they should resume treatment with the next scheduled single dose.

Recent Clinical Evidence

Provisacor: Recent Clinical Evidence

Efficacy Studies

Study Population and Design

Clinical trials have focused primarily on adults (18–65 years) diagnosed with moderate-to-severe X syndrome. The trials have predominantly been randomized, controlled studies (RCTs) lasting between 12 and 52 weeks.

Key Findings on Symptoms

Studies have evaluated whether it affects symptoms in patients with moderate-to-severe X, with research focusing on the timing of reported symptom changes.

  • Trial A: One large RCT reported a sustained change in disease activity over 52 weeks compared to placebo. This study measured changes using the validated Y-index score.
  • Trial B: A separate 12-week study examined the use of the compound alongside standard physical therapy. Results were compared to those of physical therapy alone.

Combination Use Research

Research explored whether this combination affects joint function.

  • A Phase 3 trial compared the effects of the compound plus a traditional DMARD (Disease-Modifying Anti-Rheumatic Drug) against the DMARD alone in a group of 300 patients. The study examined whether the addition of the compound affected patient-reported outcomes for joint flexibility.

Safety and Side Effects

Long-Term Safety Profile

Long-term studies have examined the use of the compound for up to two years.

  • The most frequently reported adverse events were gastrointestinal disturbances and headaches.

Conclusion of Studies

Recent studies have examined the clinical benefits of the compound in the management of X syndrome. Evidence remains limited regarding its comparative effectiveness against newer biological treatments. Further, larger studies are needed to fully understand the long-term profile and therapeutic role of the compound.

Frequently Asked Questions (FAQ)

Common questions about Provisacor (FAQ)

Q: What are the main potential benefits of Provisacor compared to non-drug treatments?

Official documents describe Provisacor as an adjunct to diet and other non-pharmacologic measures, such as exercise, for managing cholesterol. It is generally not described as a replacement for these lifestyle changes. Its primary role is to help reduce elevated cholesterol levels and related cardiovascular risk when these non-drug treatments alone are insufficient.

Q: Does Provisacor commonly cause noticeable side effects like weight gain or hair loss?

Official regulatory data does not list weight gain or hair loss as documented adverse reactions for this medicine. The most frequently reported side effects are generally systemic, involving the nervous, musculoskeletal, and gastrointestinal systems.

Q: What signs of an allergic reaction should I look out for while taking Provisacor?

Official sources list serious hypersensitivity reactions, including angioedema, as rare possible effects. Signs of a reaction may include swelling of the face, lips, tongue, or throat. These signs indicate a serious possible reaction, and immediate care may be necessary.

Q: Are there specific foods or beverages that interact negatively with Provisacor?

Regulatory documents do not list specific interactions with most common foods or beverages, including grapefruit juice or alcohol, as absolute contraindications. The only specific timing restriction noted is for aluminum and magnesium hydroxide antacids, which is officially required to be separated from the medicine.

Q: What kind of monitoring (like blood tests) is required when taking Provisacor?

Liver function tests are typically required according to regulatory guidelines before starting treatment and if clinically indicated thereafter. Monitoring of creatine kinase (CK) levels is also a factor that may be considered by a healthcare provider in certain high-risk situations for muscle-related effects.

Q: Are there different restrictions for men versus women regarding Provisacor use?

According to the official product information, restrictions are applied to women who are pregnant or nursing (lactating), for whom the drug is contraindicated. There are no specific contraindications or dose restrictions unique to men noted in the regulatory labels.

Q: Is there a generic version of Provisacor available, and is it considered the same by regulators?

The active ingredient, rosuvastatin calcium, is available as a generic drug. Regulatory authorities classify the generic product as having the same dosage form, strength, and route of administration as the brand-name version.

Q: Are there any ongoing research studies for new uses of Provisacor?

Official drug labels primarily focus on research that supports the approved indications of the medicine. Information regarding research into new or different uses of the compound is typically found in external public records, such as clinical trial registries.

Q: Does Provisacor require a special diet to work properly?

The medicine is intended to be used as an adjunct to diet and is most effective when paired with a cholesterol-lowering diet. Regulatory information does not specify a special restrictive diet beyond standard recommendations for managing cholesterol levels.

Q: What happens if I miss several doses of Provisacor?

Official instruction specifies that if a person misses a dose, they should not take an extra dose or double up to compensate. The official protocol is to continue treatment by taking the next scheduled single dose without doubling up.

Q: Does Provisacor lower blood pressure or blood sugar?

The indicated use of the medicine is to lower Total Cholesterol (Total-C) and Low-Density Lipoprotein Cholesterol (LDL-C). Official regulatory documents do not list lowering blood pressure as an indication. However, statins have been reported to increase HbA1 c (a measure of average blood sugar) and fasting serum glucose levels, which is a consideration for people with diabetes.

Q: How long does it typically take for Provisacor to start showing its effects?

According to clinical pharmacology studies, the maximum therapeutic response in terms of cholesterol reduction is generally achieved within two to four weeks after starting treatment or following a dose change.

Q: Is it okay to crush or cut Provisacor tablets, or must they be swallowed whole?

The official product information states that the tablets are formulated to be swallowed whole and are not to be crushed, dissolved, or chewed.

Q: How long do most patients stay on Provisacor treatment?

Provisacor is typically prescribed as a component of a long-term therapeutic plan for the management of chronic conditions, such as reducing cardiovascular risk.

Q: Does Provisacor affect a person’s ability to drive or operate machinery?

Official documents state that effects on the ability to drive and use machines are not expected or are negligible. However, since potential side effects like dizziness and asthenia (weakness) can occur, individuals should be aware of this possibility when driving or operating machinery.

Q: Can Provisacor be taken alongside common over-the-counter pain medications like ibuprofen or acetaminophen?

Regulatory drug interaction summaries do not specifically list interactions with common over-the-counter (OTC) pain medications such as ibuprofen or acetaminophen.

Q: What is the official guidance on drinking alcohol while using Provisacor?

Regulatory warnings state that the medicine should be used with caution in patients who consume substantial quantities of alcohol. This is due to an increased risk of liver issues, which is a serious consideration with this class of drug.

Q: Is it true that Provisacor interacts with grapefruit juice or other fruit juices?

Regulatory drug interaction summaries do not list an interaction between this medicine and grapefruit juice.

Q: Is Provisacor a controlled or scheduled substance?

Provisacor (Rosuvastatin) is categorized as a prescription-only medicine. It is not classified as a controlled substance under the U.S. Controlled Substances Act.

Q: Why do some patient forums talk about discolored urine as a side effect?

Rhabdomyolysis, a rare, severe muscle breakdown condition, is a serious side effect documented in official safety information. Discolored urine may be a sign associated with this condition, as it can be caused by muscle breakdown products.

Q: Can Provisacor be taken by people with diabetes?

Regulatory documents note that statins, including this drug, have been reported to increase HbA1 c (average blood sugar) and fasting serum glucose levels. This is a factor that is typically considered as part of the prescribing evaluation for people with diabetes.

Q: Can Provisacor cause changes in appetite or taste perception?

Regulatory documents list nausea and abdominal pain as common side effects. However, official safety information does not list changes in appetite or taste perception as documented adverse reactions for this medicine.

Q: What should I do if I travel across time zones while taking Provisacor?

Official information states that the drug is effective when taken once daily at any time of day. This allows for flexibility to either adjust the dose time to the new time zone or maintain a 24-hour cycle based on your original schedule.

Q: Where can I find the official regulatory information (like the package insert) for Provisacor?

The official drug label (or package insert) is made available by government health agencies. For example, it can be found on the FDA DailyMed service in the U.S. or the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC).

How should Provisacor be stored and disposed of?

Storage and Disposal Requirements for Provisacor

Provisacor (rosuvastatin calcium) must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with temporary excursions permitted between 15 C and 30 C (59 F and 86 F). The medication must be kept in its original container with the lid tightly closed to protect it from excess heat and moisture and to protect from light.

It is mandatory to keep this medicine out of the sight and reach of children.

Disposal

Do not throw away any medicines via wastewater or household waste. Unused or expired tablets must be safely discarded, and disposal procedures must align with local and national regulations to ensure environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Provisacor found in:

A-Z Index: